Contact Immunis

Home
About Us
Resources
Pipeline
- STEM-MYO Program
  - Phase 1/2a Clinical Trial
- STEM-META Program
  - Phase 2 Clinical Trial
News
Contact

✕

Contact Us

Our social media profiles:

Recent News

Mar 5, 2026
Immunis Licenses Treatment Candidate for Dyskinesia Associated with Parkinson’s Disease
Jan 14, 2026
Immunis Announces Preliminary Results from First-Ever Phase 2 Study of a Secretome-Based Biologic Showing Improved Gait Speed in Obese Sarcopenic Seniors
Nov 20, 2025
Immunis Named by The Healthcare Technology Report as one of the “Top 50 Healthcare Technology Companies of 2025”

Navigation

Home
About Us
Resources
Pipeline
News
Contact

Contact info

Immunis, Inc.
Irvine, California

contact@immunisbiomedical.com

Copyright © 2026 Immunis, Inc.